Sensitivity analysis of population attributable fraction in 1998 to assumptions regarding the herpes simplex virus type 2 (HSV-2) cofactor on HIV: (a) primary versus recurrent ulcers; (b) susceptibility versus infectivity; (c) absence versus presence of cofactor on HIV during HSV-2 subclinical periods
| Proportion of new HIV infections in the population attributable to HSV-2 (PAFM) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Default PAFM due to HSV-2 (%) | PAFM due to primary HSV-2 only (%) | PAFM due to recurrent HSV-2 only (%) | PAFM due to HSV-2 cofactors on HIV susceptibility only(%) | PAFM due to HSV-2 cofactors on HIV infectivity only (%) | PAFM due to default HSV-2 cofactors on HIV with the addition of the following cofactors assumed during periods between ulcerative episodes in early latent and latent stages of HSV-2 | ||||
| Effect on HIV susceptibility only | Effect on HIV susceptibility and infectivity | ||||||||
| Cofactor of 2 | Cofactor of 5 | Cofactor of 2 | Cofactor of 5 | ||||||
| M, male; F, female. | |||||||||
| Kisumu | |||||||||
| M 15–49 | 37.2 | 7.2 | 27.0 | 8.7 | 25.9 | 37.5 | 46.8 | 39.7 | 53.9 |
| F 15–49 | 37.7 | 5.8 | 26.8 | 9.0 | 23.8 | 42.4 | 49.8 | 44.4 | 54.3 |
| M and F 15–49 | 37.5 | 6.5 | 26.9 | 8.8 | 24.8 | 40.1 | 48.4 | 42.2 | 54.1 |
| Ndola | |||||||||
| M 15–49 | 35.1 | 7.3 | 26.3 | 9.1 | 24.4 | 35.6 | 43.6 | 35.4 | 49.8 |
| F 15–49 | 37.0 | 6.9 | 26.5 | 8.8 | 22.5 | 39.8 | 47.1 | 42.2 | 52.2 |
| M and F 15–49 | 36.1 | 7.1 | 26.4 | 9.0 | 23.4 | 37.9 | 45.6 | 39.1 | 51.1 |
| Cotonou | |||||||||
| M 15–49 | 52.0 | 12.0 | 41.8 | 9.6 | 40.1 | 56.1 | 62.6 | 58.9 | 69.7 |
| F 15–49 | 44.9 | 10.6 | 31.7 | 9.8 | 25.9 | 46.2 | 53.9 | 49.3 | 57.1 |
| M and F 15–49 | 47.9 | 11.2 | 36.0 | 9.7 | 31.8 | 50.3 | 57.6 | 53.4 | 62.7 |
| Yaoundé | |||||||||
| M 15–49 | 39.7 | 6.7 | 29.2 | 9.0 | 27.7 | 43.8 | 53.0 | 46.1 | 61.0 |
| F 15–49 | 36.0 | 6.0 | 26.8 | 8.6 | 22.7 | 40.1 | 50.9 | 41.9 | 56.0 |
| M and F 15–49 | 37.5 | 6.3 | 27.8 | 8.8 | 24.8 | 41.7 | 51.8 | 43.7 | 58.1 |